Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma ; volume:14 ; number:1 ; day:19 ; month:9 ; year:2024 ; pages:1-5 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (19.9.2024), 1-5, 12.2024
- Urheber
-
Hultcrantz, Malin
Hassoun, Hani
Korde, Neha
MacLachlan, Kylee
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn Rose
Chung, David J.
Lahoud, Oscar B.
Landau, Heather J.
Scordo, Michael
Shah, Gunjan L.
Giralt, Sergio
Pianko, Matthew J.
Burge, Miranda
Barnett, Kelly
Salcedo, Meghan
Caple, Julia
Tran, Linh
Blaslov, Jenna
Shekarkhand, Tala
Hamid, Selena
Nemirovsky, David
Derkach, Andriy
Arisa, Oluwatobi
Peer, Cody J.
Figg, William D.
Usmani, Saad Z.
Landgren, Ola
Lesokhin, Alexander M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01136-1
- URN
-
urn:nbn:de:101:1-2412022125474.417181253430
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hultcrantz, Malin
- Hassoun, Hani
- Korde, Neha
- MacLachlan, Kylee
- Mailankody, Sham
- Patel, Dhwani
- Shah, Urvi A.
- Tan, Carlyn Rose
- Chung, David J.
- Lahoud, Oscar B.
- Landau, Heather J.
- Scordo, Michael
- Shah, Gunjan L.
- Giralt, Sergio
- Pianko, Matthew J.
- Burge, Miranda
- Barnett, Kelly
- Salcedo, Meghan
- Caple, Julia
- Tran, Linh
- Blaslov, Jenna
- Shekarkhand, Tala
- Hamid, Selena
- Nemirovsky, David
- Derkach, Andriy
- Arisa, Oluwatobi
- Peer, Cody J.
- Figg, William D.
- Usmani, Saad Z.
- Landgren, Ola
- Lesokhin, Alexander M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide